fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 30. More products

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Levodopa & carbidopa

18 general benefit · 2 Limited Use · 4 not a benefit

AA-Levocarb CR · DIN 02272873 · 100 mg & 25 mg · CR tablet

Limited Use, Reason for Use code 64, 65 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 64, 65 required
Write on scriptone applicable Reason for Use code, 64 or 65 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 64, 65
Reason for Use code 64 For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 65 For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
AA-Levocarb CR · DIN 02272873 Manufacturer: A A Pharma Inc.; listing date 2009-08-18 Health Canada: Marketed since 2020-05-26 · brand AA-LEVOCARB CR · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet (extended-release) · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 100 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

AA-Levocarb CR: Formulary list price $0.80 per unit (the source does not state the unit; exact figure $0.7974). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02272873)

Source record
DIN 02272873: AA-Levocarb CR Raw flags: sec12=Y, sec3=Y Item: 920000218; group id 931; item number 2219; lccId 00130; manufacturer id AAP Source form: CR Tab; strength: 100mg & 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.7974; ministry $0.7974 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02272873 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75839
Interchangeable products
Sinemet CR · DIN 02028786 · not recorded
Shortage status: resolved shortage (ended March 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02272873
Shortage record checked October 6, 2026

Apo-Levocarb · DIN 02195933 · 100 mg & 10 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Levocarb · DIN 02195933 Manufacturer: Apotex Inc.; listing date 1996-12-19 Health Canada: Marketed since 2024-08-27 · brand APO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Levocarb: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02195933)

Source record
DIN 02195933: Apo-Levocarb Raw flags: sec3=Y Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id APX Source form: Tab; strength: 100mg & 10mg Recorded listing: General benefit Source prices (unrounded): $0.1479; ministry $0.1479 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02195933 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20189
Interchangeable products
Auro-Levocarb · DIN 02531593 · $0.1479 Jamp Levocarb · DIN 02546396 · $0.1479 Mint-Levocarb · DIN 02457954 · $0.1479 PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479 Sinemet · DIN 00355658 · not recorded Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02195933
Shortage record checked October 6, 2026

Apo-Levocarb · DIN 02195941 · 100 mg & 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Levocarb · DIN 02195941 Manufacturer: Apotex Inc.; listing date 1996-12-19 Health Canada: Marketed since 2024-08-27 · brand APO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 100 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Levocarb: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02195941)

Source record
DIN 02195941: Apo-Levocarb Raw flags: sec3=Y Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id APX Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2209; ministry $0.2209 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02195941 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20239
Interchangeable products
Auro-Levocarb · DIN 02531607 · $0.2209 Jamp Levocarb · DIN 02546418 · $0.2209 Mint-Levocarb · DIN 02457962 · $0.2209 PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209 Sinemet · DIN 00513997 · not recorded Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: resolved shortage (ended October 3, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02195941
Shortage record checked October 6, 2026

Auro-Levocarb · DIN 02531593 · 100 mg & 10 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Levocarb · DIN 02531593 Manufacturer: Auro Pharma Inc.; listing date 2023-06-30 Health Canada: Marketed since 2023-04-28 · brand AURO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Levocarb: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531593)

Source record
DIN 02531593: Auro-Levocarb Raw flags: sec3=Y Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id AUR Source form: Tab; strength: 100mg & 10mg Recorded listing: General benefit Source prices (unrounded): $0.1479; ministry $0.1479 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531593 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102071
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479 Jamp Levocarb · DIN 02546396 · $0.1479 Mint-Levocarb · DIN 02457954 · $0.1479 PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479 Sinemet · DIN 00355658 · not recorded Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: resolved shortage (ended April 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531593
Shortage record checked October 6, 2026

Auro-Levocarb · DIN 02531607 · 100 mg & 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Levocarb · DIN 02531607 Manufacturer: Auro Pharma Inc.; listing date 2023-06-30 Health Canada: Marketed since 2023-04-14 · brand AURO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 25 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Levocarb: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531607)

Source record
DIN 02531607: Auro-Levocarb Raw flags: sec3=Y Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id AUR Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2209; ministry $0.2209 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531607 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102072
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209 Jamp Levocarb · DIN 02546418 · $0.2209 Mint-Levocarb · DIN 02457962 · $0.2209 PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209 Sinemet · DIN 00513997 · not recorded Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: resolved shortage (ended April 15, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531607
Shortage record checked October 6, 2026

Jamp Levocarb · DIN 02546396 · 100 mg & 10 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Levocarb · DIN 02546396 Manufacturer: Jamp Pharma Corporation; listing date 2025-01-31 Health Canada: Marketed since 2024-12-13 · brand JAMP LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Levocarb: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02546396)

Source record
DIN 02546396: Jamp Levocarb Raw flags: sec3=Y Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id JPC Source form: Tab; strength: 100mg & 10mg Recorded listing: General benefit Source prices (unrounded): $0.1479; ministry $0.1479 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02546396 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103509
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479 Auro-Levocarb · DIN 02531593 · $0.1479 Mint-Levocarb · DIN 02457954 · $0.1479 PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479 Sinemet · DIN 00355658 · not recorded Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02546396
Shortage record checked October 6, 2026

Jamp Levocarb · DIN 02546418 · 100 mg & 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Levocarb · DIN 02546418 Manufacturer: Jamp Pharma Corporation; listing date 2025-01-31 Health Canada: Marketed since 2024-12-13 · brand JAMP LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 25 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Levocarb: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02546418)

Source record
DIN 02546418: Jamp Levocarb Raw flags: sec3=Y Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id JPC Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2209; ministry $0.2209 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02546418 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103510
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209 Auro-Levocarb · DIN 02531607 · $0.2209 Mint-Levocarb · DIN 02457962 · $0.2209 PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209 Sinemet · DIN 00513997 · not recorded Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02546418
Shortage record checked October 6, 2026

Mint-Levocarb · DIN 02457954 · 100 mg & 10 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mint-Levocarb · DIN 02457954 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2017-02-28 Health Canada: Marketed since 2026-01-12 · brand MINT-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Levocarb: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02457954)

Source record
DIN 02457954: Mint-Levocarb Raw flags: sec3=Y Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id MIN Source form: Tab; strength: 100mg & 10mg Recorded listing: General benefit Source prices (unrounded): $0.1479; ministry $0.1479 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457954 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94498
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479 Auro-Levocarb · DIN 02531593 · $0.1479 Jamp Levocarb · DIN 02546396 · $0.1479 PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479 Sinemet · DIN 00355658 · not recorded Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: resolved shortage (ended January 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457954
Shortage record checked October 6, 2026

Mint-Levocarb · DIN 02457962 · 100 mg & 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mint-Levocarb · DIN 02457962 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2017-02-28 Health Canada: Marketed since 2024-09-20 · brand MINT-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 100 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Levocarb: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02457962)

Source record
DIN 02457962: Mint-Levocarb Raw flags: sec3=Y Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id MIN Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2209; ministry $0.2209 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457962 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94499
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209 Auro-Levocarb · DIN 02531607 · $0.2209 Jamp Levocarb · DIN 02546418 · $0.2209 PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209 Sinemet · DIN 00513997 · not recorded Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: resolved shortage (ended September 20, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457962
Shortage record checked October 6, 2026

PMS-Levodopa-Carbidopa · DIN 02549719 · 100 mg & 10 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PMS-Levodopa-Carbidopa · DIN 02549719 Manufacturer: Pharmascience Inc.; listing date 2025-04-30 Health Canada: Marketed since 2025-03-05 · brand PMS-LEVODOPA-CARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Levodopa-Carbidopa: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02549719)

Source record
DIN 02549719: PMS-Levodopa-Carbidopa Raw flags: sec3=Y Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id PMS Source form: Tab; strength: 100mg & 10mg Recorded listing: General benefit Source prices (unrounded): $0.1479; ministry $0.1479 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02549719 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103853
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479 Auro-Levocarb · DIN 02531593 · $0.1479 Jamp Levocarb · DIN 02546396 · $0.1479 Mint-Levocarb · DIN 02457954 · $0.1479 Sinemet · DIN 00355658 · not recorded Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549719
Shortage record checked October 6, 2026

PMS-Levodopa-Carbidopa · DIN 02549727 · 100 mg & 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PMS-Levodopa-Carbidopa · DIN 02549727 Manufacturer: Pharmascience Inc.; listing date 2025-04-30 Health Canada: Marketed since 2025-03-05 · brand PMS-LEVODOPA-CARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 100 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Levodopa-Carbidopa: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02549727)

Source record
DIN 02549727: PMS-Levodopa-Carbidopa Raw flags: sec3=Y Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id PMS Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2209; ministry $0.2209 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02549727 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103854
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209 Auro-Levocarb · DIN 02531607 · $0.2209 Jamp Levocarb · DIN 02546418 · $0.2209 Mint-Levocarb · DIN 02457962 · $0.2209 Sinemet · DIN 00513997 · not recorded Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549727
Shortage record checked October 6, 2026

Teva-Levocarbidopa · DIN 02244495 · 100 mg & 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Levocarbidopa · DIN 02244495 Manufacturer: Teva Canada Limited; listing date 2003-01-30 Health Canada: Marketed since 2011-12-13 · brand TEVA-LEVOCARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 25 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Levocarbidopa: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2209). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244495)

Source record
DIN 02244495: Teva-Levocarbidopa Raw flags: sec3=Y Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id TEV Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2209; ministry $0.2209 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244495 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68471
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209 Auro-Levocarb · DIN 02531607 · $0.2209 Jamp Levocarb · DIN 02546418 · $0.2209 Mint-Levocarb · DIN 02457962 · $0.2209 PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209 Sinemet · DIN 00513997 · not recorded
Shortage status: active shortage (reported November 28, 2019, last updated August 18, 2022) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244495
Shortage record checked October 6, 2026

AA-Levocarb CR · DIN 02245211 · 200 mg & 50 mg · CR tablet

Limited Use, Reason for Use code 64, 65 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 64, 65 required
Write on scriptone applicable Reason for Use code, 64 or 65 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 64, 65
Reason for Use code 64 For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 65 For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
AA-Levocarb CR · DIN 02245211 Manufacturer: A A Pharma Inc.; listing date 2004-07-20 Health Canada: Marketed since 2020-06-12 · brand AA-LEVOCARB CR · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet (extended-release) · route Oral · ingredients LEVODOPA 200 MG, CARBIDOPA 50 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

AA-Levocarb CR: Formulary list price $1.43 per unit (the source does not state the unit; exact figure $1.4282). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245211)

Source record
DIN 02245211: AA-Levocarb CR Raw flags: sec12=Y, sec3=Y Item: 920000217; group id 931; item number 2220; lccId 00130; manufacturer id AAP Source form: CR Tab; strength: 200mg & 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.4282; ministry $1.4282 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245211 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69226
Interchangeable products
Sinemet CR · DIN 00870935 · not recorded
Shortage status: resolved shortage (ended January 2, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245211
Shortage record checked October 6, 2026

Apo-Levocarb · DIN 02195968 · 250 mg & 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Levocarb · DIN 02195968 Manufacturer: Apotex Inc.; listing date 1996-12-19 Health Canada: Marketed since 2024-08-27 · brand APO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 250 MG, CARBIDOPA 25 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Levocarb: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02195968)

Source record
DIN 02195968: Apo-Levocarb Raw flags: sec3=Y Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id APX Source form: Tab; strength: 250mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2466; ministry $0.2466 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02195968 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20190
Interchangeable products
Auro-Levocarb · DIN 02531615 · $0.2466 Jamp Levocarb · DIN 02546426 · $0.2466 Mint-Levocarb · DIN 02457970 · $0.2466 PMS-Levodopa-Carbidopa · DIN 02549735 · $0.2466 Sinemet · DIN 00328219 · not recorded Teva-Levocarbidopa · DIN 02244496 · $0.2466
Shortage status: resolved shortage (ended May 7, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02195968
Shortage record checked October 6, 2026

Auro-Levocarb · DIN 02531615 · 250 mg & 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Levocarb · DIN 02531615 Manufacturer: Auro Pharma Inc.; listing date 2023-06-30 Health Canada: Marketed since 2023-04-14 · brand AURO-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 250 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Levocarb: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02531615)

Source record
DIN 02531615: Auro-Levocarb Raw flags: sec3=Y Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id AUR Source form: Tab; strength: 250mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2466; ministry $0.2466 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02531615 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102073
Interchangeable products
Apo-Levocarb · DIN 02195968 · $0.2466 Jamp Levocarb · DIN 02546426 · $0.2466 Mint-Levocarb · DIN 02457970 · $0.2466 PMS-Levodopa-Carbidopa · DIN 02549735 · $0.2466 Sinemet · DIN 00328219 · not recorded Teva-Levocarbidopa · DIN 02244496 · $0.2466
Shortage status: resolved shortage (ended April 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531615
Shortage record checked October 6, 2026

Jamp Levocarb · DIN 02546426 · 250 mg & 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Levocarb · DIN 02546426 Manufacturer: Jamp Pharma Corporation; listing date 2025-01-31 Health Canada: Marketed since 2024-12-13 · brand JAMP LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 250 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Levocarb: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02546426)

Source record
DIN 02546426: Jamp Levocarb Raw flags: sec3=Y Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id JPC Source form: Tab; strength: 250mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2466; ministry $0.2466 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02546426 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103511
Interchangeable products
Apo-Levocarb · DIN 02195968 · $0.2466 Auro-Levocarb · DIN 02531615 · $0.2466 Mint-Levocarb · DIN 02457970 · $0.2466 PMS-Levodopa-Carbidopa · DIN 02549735 · $0.2466 Sinemet · DIN 00328219 · not recorded Teva-Levocarbidopa · DIN 02244496 · $0.2466
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02546426
Shortage record checked October 6, 2026

PMS-Levodopa-Carbidopa · DIN 02549735 · 250 mg & 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
PMS-Levodopa-Carbidopa · DIN 02549735 Manufacturer: Pharmascience Inc.; listing date 2025-04-30 Health Canada: Marketed since 2025-03-05 · brand PMS-LEVODOPA-CARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 250 MG, CARBIDOPA 25 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Levodopa-Carbidopa: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02549735)

Source record
DIN 02549735: PMS-Levodopa-Carbidopa Raw flags: sec3=Y Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id PMS Source form: Tab; strength: 250mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2466; ministry $0.2466 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02549735 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103855
Interchangeable products
Apo-Levocarb · DIN 02195968 · $0.2466 Auro-Levocarb · DIN 02531615 · $0.2466 Jamp Levocarb · DIN 02546426 · $0.2466 Mint-Levocarb · DIN 02457970 · $0.2466 Sinemet · DIN 00328219 · not recorded Teva-Levocarbidopa · DIN 02244496 · $0.2466
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549735
Shortage record checked October 6, 2026

Teva-Levocarbidopa · DIN 02244496 · 250 mg & 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Levocarbidopa · DIN 02244496 Manufacturer: Teva Canada Limited; listing date 2002-07-29 Health Canada: Marketed since 2011-12-13 · brand TEVA-LEVOCARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 250 MG, CARBIDOPA 25 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Levocarbidopa: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244496)

Source record
DIN 02244496: Teva-Levocarbidopa Raw flags: sec3=Y Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id TEV Source form: Tab; strength: 250mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2466; ministry $0.2466 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244496 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68472
Interchangeable products
Apo-Levocarb · DIN 02195968 · $0.2466 Auro-Levocarb · DIN 02531615 · $0.2466 Jamp Levocarb · DIN 02546426 · $0.2466 Mint-Levocarb · DIN 02457970 · $0.2466 PMS-Levodopa-Carbidopa · DIN 02549735 · $0.2466 Sinemet · DIN 00328219 · not recorded
Shortage status: discontinued (June 12, 2019, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244496
Shortage record checked October 6, 2026

Teva-Levocarbidopa · DIN 02244494 · 100 mg & 10 mg · tablet

General benefitDormant since February 28, 2024 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Levocarbidopa · DIN 02244494 Manufacturer: Teva Canada Limited; listing date 2003-01-30 Health Canada: Dormant since 2024-02-28 · brand TEVA-LEVOCARBIDOPA · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 10 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Levocarbidopa: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1479). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02244494)

Source record
DIN 02244494: Teva-Levocarbidopa Raw flags: sec3=Y Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id TEV Source form: Tab; strength: 100mg & 10mg Recorded listing: General benefit Source prices (unrounded): $0.1479; ministry $0.1479 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02244494 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68470
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479 Auro-Levocarb · DIN 02531593 · $0.1479 Jamp Levocarb · DIN 02546396 · $0.1479 Mint-Levocarb · DIN 02457954 · $0.1479 PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479 Sinemet · DIN 00355658 · not recorded
Shortage status: active shortage (reported March 25, 2020, last updated March 26, 2020) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244494
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since February 28, 2024 — choose a marketed DIN from the same-category list.

Mint-Levocarb · DIN 02457970 · 250 mg & 25 mg · tablet

General benefitDormant since August 1, 2017 · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Mint-Levocarb · DIN 02457970 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2017-02-28 Health Canada: Dormant since 2017-08-01 · brand MINT-LEVOCARB · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 250 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mint-Levocarb: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2466). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02457970)

Source record
DIN 02457970: Mint-Levocarb Raw flags: sec3=Y Item: 920000022; group id 932; item number 2223; lccId None; manufacturer id MIN Source form: Tab; strength: 250mg & 25mg Recorded listing: General benefit Source prices (unrounded): $0.2466; ministry $0.2466 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02457970 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94500
Interchangeable products
Apo-Levocarb · DIN 02195968 · $0.2466 Auro-Levocarb · DIN 02531615 · $0.2466 Jamp Levocarb · DIN 02546426 · $0.2466 PMS-Levodopa-Carbidopa · DIN 02549735 · $0.2466 Sinemet · DIN 00328219 · not recorded Teva-Levocarbidopa · DIN 02244496 · $0.2466
Shortage status: active shortage (reported December 8, 2020, estimated to end November 30, 2026, last updated June 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457970
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 1, 2017 — choose a marketed DIN from the same-category list.

Sinemet CR · DIN 02028786 · 100 mg & 25 mg · CR tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-31 — choose a marketed DIN from the same-category list.Discontinued October 31, 2019 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-31 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2019-10-31 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; the ministry's EAP drug list names this generic but not this DIN: confirm the product before an EAP request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Ontario Limited Use criteria, code 64, 65
Reason for Use code 64 For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 65 For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Sinemet CR · DIN 02028786 Manufacturer: Merck Frosst Canada Ltd.; listing date 1996-10-01 Health Canada: Cancelled post market since 2019-10-31 · brand SINEMET CR 100/25 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet (extended-release) · route Oral · ingredients CARBIDOPA 25 MG, LEVODOPA 100 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sinemet CR: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02028786)

Source record
DIN 02028786: Sinemet CR Raw flags: notABenefit=Y, sec3=Y Item: 920000218; group id 931; item number 2219; lccId 00130; manufacturer id MFC Source form: CR Tab; strength: 100mg & 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02028786 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14082
Interchangeable products
AA-Levocarb CR · DIN 02272873 · $0.7974
Shortage status: discontinued (October 31, 2019, reported by MERCK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02028786
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since October 31, 2019 — choose a marketed DIN from the same-category list.

Sinemet · DIN 00355658 · 100 mg & 10 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-06-16 — choose a marketed DIN from the same-category list.Discontinued June 16, 2017 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-06-16 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2017-06-16 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; the ministry's EAP drug list names this generic but not this DIN: confirm the product before an EAP request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Sinemet · DIN 00355658 Manufacturer: Merck Frosst Canada Ltd.; listing date 1996-10-01 Health Canada: Cancelled post market since 2017-06-16 · brand SINEMET 100/10 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients CARBIDOPA 10 MG, LEVODOPA 100 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sinemet: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00355658)

Source record
DIN 00355658: Sinemet Raw flags: notABenefit=Y, sec3=Y Item: 920000030; group id 932; item number 2221; lccId None; manufacturer id MFC Source form: Tab; strength: 100mg & 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00355658 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3331
Interchangeable products
Apo-Levocarb · DIN 02195933 · $0.1479 Auro-Levocarb · DIN 02531593 · $0.1479 Jamp Levocarb · DIN 02546396 · $0.1479 Mint-Levocarb · DIN 02457954 · $0.1479 PMS-Levodopa-Carbidopa · DIN 02549719 · $0.1479 Teva-Levocarbidopa · DIN 02244494 · $0.1479
Shortage status: discontinued (June 19, 2017, reported by MERCK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00355658
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 16, 2017 — choose a marketed DIN from the same-category list.

Sinemet · DIN 00513997 · 100 mg & 25 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-27 — choose a marketed DIN from the same-category list.Discontinued July 27, 2022 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-07-27 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2022-07-27 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; the ministry's EAP drug list names this generic but not this DIN: confirm the product before an EAP request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Sinemet · DIN 00513997 Manufacturer: Organon Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2022-07-27 · brand SINEMET · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet · route Oral · ingredients LEVODOPA 100 MG, CARBIDOPA 25 MG · company Organon canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sinemet: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00513997)

Source record
DIN 00513997: Sinemet Raw flags: notABenefit=Y, sec3=Y Item: 920000036; group id 932; item number 2222; lccId None; manufacturer id OCI Source form: Tab; strength: 100mg & 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00513997 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4008
Interchangeable products
Apo-Levocarb · DIN 02195941 · $0.2209 Auro-Levocarb · DIN 02531607 · $0.2209 Jamp Levocarb · DIN 02546418 · $0.2209 Mint-Levocarb · DIN 02457962 · $0.2209 PMS-Levodopa-Carbidopa · DIN 02549727 · $0.2209 Teva-Levocarbidopa · DIN 02244495 · $0.2209
Shortage status: discontinued (July 27, 2022, reported by ORGANON CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00513997
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 27, 2022 — choose a marketed DIN from the same-category list.

Sinemet CR · DIN 00870935 · 200 mg & 50 mg · CR tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-02-22 — choose a marketed DIN from the same-category list.Discontinued February 22, 2019 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-02-22 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2019-02-22 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; the ministry's EAP drug list names this generic but not this DIN: confirm the product before an EAP request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Ontario Limited Use criteria, code 64, 65
Reason for Use code 64 For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 65 For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Sinemet CR · DIN 00870935 Manufacturer: Merck Frosst Canada Ltd.; listing date 1996-10-01 Health Canada: Cancelled post market since 2019-02-22 · brand SINEMET CR 200/50 · ATC N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR · form Tablet (extended-release) · route Oral · ingredients LEVODOPA 200 MG, CARBIDOPA 50 MG · company Merck canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sinemet CR: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00870935)

Source record
DIN 00870935: Sinemet CR Raw flags: notABenefit=Y, sec3=Y Item: 920000217; group id 931; item number 2220; lccId 00130; manufacturer id MFC Source form: CR Tab; strength: 200mg & 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00870935 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11481
Interchangeable products
AA-Levocarb CR · DIN 02245211 · $1.4282
Shortage status: resolved shortage (ended April 1, 2019); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00870935
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 22, 2019 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N04B, N04BA): coverage varies; not interchangeable

  • Benserazide + levodopa (Prolopa 50-12.5): general benefit
  • Amantadine (Symmetrel): general benefit, not a benefit
  • Bromocriptine (Parlodel): general benefit, not a benefit
  • Ropinirole (ReQuip): general benefit, not a benefit
  • Selegiline (Eldepryl): general benefit, not a benefit
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

ROPINIROLE

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 0.25mg, 1mg, 2mg, 5mg · Tab

SELEGILINE HCL

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 77 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: parkinsons disease
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BROMOCRIPTINE · Listed, not a benefit (2), General benefit (2)  Parkinson’s Disease: BROMOCRIPTINE is effective when used as adjunct therapy to levodopa in the symptomatic management of Parkinson’s Disease. Used concomitantly with levodopa, bromocriptine facilitates the use of lower doses of levodopa in early disease and attenuates the rate of increase in the levodopa dosages on long-term usage. In this way the risk of long– term complications such as prominent dyskinesias and/or end-of-dose failure can be reduced. PM: https://pdf.hres.ca/dpd_pm/00064762.PDF; date FEB 16, 2022; DIN 02087324; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS APO-LEVOCARB (levodopa and carbidopa tablets) is indicated for the treatment of Parkinson's disease. APO-LEVOCARB is not recommended for the treatment of drug-induced extrapyramidal reactions. 1.1 Pediatrics Pediatrics (< 18 years of age): The safety and effectiveness of levodopa and carbidopa in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical studies and experience with levodopa and carbidopa combinations suggest that use in the geriatric population is not associated with differences in safety or effectiveness (see 4.2 Recommended Dose and Dosage Adjustment, Geriatrics). https://pdf.hres.ca/dpd_pm/00076848.PDF PM date: AUG 27, 2024 Source product: APO-LEVOCARB; DIN 02195933; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE STALEVO® (levodopa, carbidopa and entacapone) is indicated to treat patients with idiopathic Parkinson’s disease: • To substitute for immediate-release levodopa/carbidopa and entacapone previously administered as individual products. • To replace immediate-release levodopa/carbidopa therapy (without entacapone) when patients experience the signs and symptoms of end of dose "wearing off" (only recommended when patients are taking a total daily dose of levodopa of 600 mg or less and not experiencing dyskinesias, see DOSAGE AND ADMINISTRATION). Geriatrics: No adjustment of STALEVO dosage is necessary in elderly patients. Pediatrics (< 18 years of age): Safety and effectiveness in pediatric patients have not been established. STALEVO is not indicated for use in children under 18 years of age. https://pdf.hres.ca/dpd_pm/00057237.PDF PM date: July 21, 2020 Source product: STALEVO; DIN 02305933; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Levocarbidopa · DIN 02244495 Shortage status: active shortage (reported 2019-11-28, last updated 2022-08-18) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244495

Check this DIN again

Teva-Levocarbidopa · DIN 02244496 Shortage status: discontinued (2019-06-12, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244496

Check this DIN again

Teva-Levocarbidopa · DIN 02244494 Shortage status: active shortage (reported 2020-03-25, last updated 2020-03-26) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02244494

Check this DIN again

Mint-Levocarb · DIN 02457970 Shortage status: active shortage (reported 2020-12-08, estimated to end 2026-11-30, last updated 2026-06-17); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457970

Check this DIN again

Sinemet CR · DIN 02028786 Shortage status: discontinued (2019-10-31, reported by MERCK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02028786

Check this DIN again

Sinemet · DIN 00355658 Shortage status: discontinued (2017-06-19, reported by MERCK CANADA INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00355658

Check this DIN again

Sinemet · DIN 00513997 Shortage status: discontinued (2022-07-27, reported by ORGANON CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00513997

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Sinemet CR, Sinemet: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026